surmount 5 tirzepatide SURMOUNT-5 (NCT05822830) was a multi-center, randomized, open-label, phase 3b trial evaluating the efficacy and safety of #Zepbound® (tirzepatide) compared with #Wegovy® (semaglutide, similar to full dose #ozempic) in adults with obesity + ESC 2025: post-hoc SURMOUNT-5 data

The oak wood intervention also resulted in significant improvement in the liver enzymes AST and ALT, and in the liver fibrosis index, compared to the standard management group

Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist consisting of 31 amino acids, structurally modified from native GLP-1 to extend its half-life through albumin binding

Mizuno T, Cloyd JM, Vicente D, Omichi K, Chun YS, Kopetz SE , Maru D, Conrad C, Tzeng CD, Wei SH, Aloia TA, Vauthey JN

This pathway is separate from and synergistic with the GHRH pathway

MAIT cell inhibition promotes liver fibrosis regression via macrophage phenotype reprogramming